Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome
TLDR
The terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe as discussed by the authors.Abstract:
Background The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe. Methods We...read more
Citations
More filters
Journal ArticleDOI
Acute-on-Chronic Liver Failure Clinical Guidelines
Jasmohan S. Bajaj,Jacqueline G. O'Leary,Jennifer C. Lai,Florence Wong,Millie D. Long,Robert J. Wong,Patrick S. Kamath +6 more
TL;DR: These guidelines indicate the preferred approach to the management of patients with acute-on-chronic liver failure and represent the official practice recommendations of the American College of Gastroenterology.
Journal ArticleDOI
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure
Florence Wong,S. Chris Pappas,K. Rajender Reddy,Hugo E. Vargas,Michael P. Curry,Arun J. Sanyal,Khurram Jamil +6 more
TL;DR: This data indicates that liver transplantation in patients with hepatorenal syndrome type 1 (HRS1) and advanced acute‐on‐chronic liver failure (ACLF) requires further study to establish a causative mechanism.
Journal ArticleDOI
Norepinephrine is More Effective Than Midodrine/Octreotide in Patients With Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial.
TL;DR: In this article, the authors compared the efficacy of midodrine/octreotide to that of norepinephrine for the treatment of patients with hepatorenal syndrome and found that nore pinephrine plus albumin is significantly more effective in improving renal function in patients with liver failure.
Journal ArticleDOI
Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome.
TL;DR: In this paper, the authors evaluated the real-life effectiveness of a sequential vasoconstrictor regimen of midodrine-Octreotide followed by norepinephrine in a nonintensive care unit (non-ICU) setting in the United States, where terlipressin is not available.
Journal ArticleDOI
Review article: current and emerging therapies for the management of cirrhosis and its complications
TL;DR: Cirrhosis is increasingly common and morbid and optimal utilisation of therapeutic strategies to prevent and control the complications of cirrhosis are central to improving clinical and patient‐reported outcomes.